Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Xiaolan Yong"'
Autor:
Xiaolan Yong, Jun Liu, Ying Zeng, Jing Nie, Xuelian Cui, Tao Wang, Yilin Wang, Yiyong Chen, Wei Kang, Zhonghua Yang, Yan Liu
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 3 (2023)
LYB001 is an innovative recombinant SARS-CoV-2 vaccine that displays a repetitive array of the spike glycoprotein’s receptor-binding domain (RBD) on a virus-like particle (VLP) vector to boost the immune system, produced using Covalink plug-and-dis
Externí odkaz:
https://doaj.org/article/84a2e0b5d3f744cc9946a4533fed70ed
Autor:
Xin Wang, Ying Wang, Xiaolan Yong, Bojun Wu, Zilin Sun, Ning Lou, Qing Wen, Yufang Zhang, Shiyun Li, Jiarui Li, Yan He, Jinluo Cheng, Xiangdong Zhong, Jing Shen, Wenying Yang
Publikováno v:
Journal of Diabetes, Vol 14, Iss 12, Pp 822-830 (2022)
Abstract Background The new xanthine dipeptidyl peptidase‐4 inhibitor yogliptin has exhibited excellent hypoglycemic activity in experimental disease models. The present work aimed to assess the efficacy of yogliptin as a monotherapy in individuals
Externí odkaz:
https://doaj.org/article/7cc74c7dbeac4893b9af0ab13fe17629
Autor:
Xin Wang, Ying Wang, Xiaolan Yong, Bojun Wu, Zilin Sun, Ning Lou, Qing Wen, Yufang Zhang, Shiyun Li, Jiarui Li, Yan He, Jinluo Cheng, Xiangdong Zhong, Jing Shen, Wenying Yang
Publikováno v:
Journal of Diabetes. 14:822-830
The new xanthine dipeptidyl peptidase-4 inhibitor yogliptin has exhibited excellent hypoglycemic activity in experimental disease models. The present work aimed to assess the efficacy of yogliptin as a monotherapy in individuals with type 2 diabetes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d43f5de88ddb6dfaa131a4bd49570b92
https://doi.org/10.1111/1753-0407.13337
https://doi.org/10.1111/1753-0407.13337
Autor:
Xiaolan Yong1, Tingting Hu1, Shiyin Feng1, Xiaolin Du1, Huiqing Shi1, Wang Feng2 wangfeng8799@163.com
Publikováno v:
Tropical Journal of Pharmaceutical Research. Aug2015, Vol. 14 Issue 8, p1481-1486. 6p.
Autor:
Han ZHANG, XiaoLan YONG
Publikováno v:
Pharmaceutical Care and Research. 15:411-447
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e0283c29cc2f34a17796b3a32bf5a4c
https://doi.org/10.5428/pcar20150604
https://doi.org/10.5428/pcar20150604
Autor:
Juan Huang, Minquan Wang, Lantian Wang, Xiaolan Yong, Aidong Wen, Ying Chen, Huaqiong Shen, Yan-Ping Liu, Jia Li, Xiaojiao Dai, Haiyan Liu, Tingting Hu, Xiangyang Liu, Nan Li
Publikováno v:
Clinical drug investigation. 36(3)
Henagliflozin, a selective inhibitor of the renal sodium glucose cotransporter-2, was developed for type 2 diabetes mellitus (T2DM). This study characterized single- and multiple-dose pharmacokinetics and pharmacodynamics of henagliflozin in Chinese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d46346cfcefa9640b698f36e8f5b499
https://pubmed.ncbi.nlm.nih.gov/26692004
https://pubmed.ncbi.nlm.nih.gov/26692004
Publikováno v:
Pharmaceutical Care and Research. 13:336-338
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::330a8b7f31e04fd77a9b7294fd478830
https://doi.org/10.5428/pcar20130505
https://doi.org/10.5428/pcar20130505
Publikováno v:
Annals of Clinical Microbiology & Antimicrobials; 2015, Vol. 14 Issue 1, p55-64, 10p
Autor:
Wang, Xin1 (AUTHOR), Wang, Ying2 (AUTHOR), Yong, Xiaolan3 (AUTHOR), Wu, Bojun3 (AUTHOR), Sun, Zilin4 (AUTHOR), Lou, Ning5 (AUTHOR), Wen, Qing5 (AUTHOR), Zhang, Yufang6 (AUTHOR), Li, Shiyun7 (AUTHOR), Li, Jiarui8 (AUTHOR), He, Yan9 (AUTHOR), Cheng, Jinluo10 (AUTHOR), Zhong, Xiangdong10 (AUTHOR), Shen, Jing11 (AUTHOR), Yang, Wenying1 (AUTHOR) ywying_1010@163.com
Publikováno v:
Journal of Diabetes. Dec2022, Vol. 14 Issue 12, p822-830. 9p.
Publikováno v:
Diabetes; 2015 Supplement, Vol. 64, pA300-A336, 37p, 49 Charts, 12 Graphs